Totaria highlights four factors in choosing midlife supplements
Totaria advises women choosing midlife supplements to consider formulation, labeling, serving size, and ease of use—not just ingredient count.
Women's Health
Seya Health launches Full Fiber
Austin-based women's health brand debuts at $24.99 on Seyahealth.com and Amazon, with female-focused creatine and hormone support formulas set for pipeline rollout.
Uqora report highlights hidden toll of UTIs on women’s health and daily lives
According to Uqora's UTI Impact Report, nearly half of women are willing to take a proactive approach to urinary health, signaling growing interest in prevention rather than treatment alone.
Deloitte: Better women’s healthcare could create $527B opportunity
Proactive, life-stage-aware care could improve outcomes, reduce downstream costs and may support a modeled health span increase of up to 20 years.
Always and Tampax put period preparedness on the college checklist
The back-to-school effort brings practical period education, trusted products and peer advice to students as they navigate greater independence on campus.
Nature’s Bounty launches women’s health education campaign
Half of the women surveyed said they do not always fully understand how their bodies work or what they need to support overall wellness.
Select Bonafide Health products named the most recommended in their category
Bonafide’s Revaree and Revaree Plus have both been named the No. 1 Gynecologist recommended OTC hyaluronic acid insert for vaginal dryness.
FemiClear acquired by Venture Life Group to expand women’s health platform
Venture Life Group acquired FemiClear and CUROXEN, boosting its self-care portfolio and U.S. women's health market presence.
Kearney unveils Women’s Health Healthcare and Life Sciences Index
New report tracks how gender-responsive practices that improve the health of women are embedded across pharma, MedTech, consumer health, payor, provider, and investor value chains.
Kearney study exposes major gaps in women’s health funding and innovation
$34 billion in private capital investments have not been aligned with disease burden priorities.